Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.
about
Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicityOnset of Manic Episode during Chemotherapy with 5-FluorouracilSevere encephalopathy, lactic acidosis, vegetative instability and neuropathy with 5-Fluorouracil treatment - pyrimidine degradation defect or beriberi?Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisoleFluorouracil-induced neurotoxicityMultifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisoleHigh-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathyAcute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.Fluorescence lifetime microscopy of NADH distinguishes alterations in cerebral metabolism in vivo.A case of 5-fluorouracil induced encephalopathy.Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil.S-1 in gastric cancer: a comprehensive review.Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.Toxicology of fluoroacetate: a review, with possible directions for therapy research.Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.Cerebral demyelination with 5-fluorouracil and levamisole.Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.The confused cancer patient: a case of 5-fluorouracil-induced encephalopathy5-fu metabolism in cancer and orally-administrable 5-fu drugs.S-1 as a core anticancer fluoropyrimidine agent.Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.Epilepsy in women with gynecologic malignancies.Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structureDevelopment history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas.Prevention of 5-fluorouracil-caused growth inhibition in Sordaria fimicolaFluorouracil cardiotoxicity.The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy.Hepatic encephalopathy associated with cancer or anticancer therapy.Two cases of Wernicke's encephalopathy in young age patients receiving allogeneic hematopoietic stem cell transplantation.The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.Wernicke-Korsakoff-like syndrome in patients with colorectal carcinoma treated with high-dose doxifluridine (5'-dFUrd).Bilateral Blindness Following Chemoradiation for Locally Advanced Oropharyngeal Carcinoma.5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus.Use of capecitabine after renal allograft transplantation in dog erythrocyte antigen-matched dogs.Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients.Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.Drug delivery of oral anti-cancer fluoropyrimidine agents.
P2860
Q24561644-504DB1B4-729D-4360-9E42-5E51F0AD54C3Q24613030-0926A6F7-9CCB-44FC-A7E8-6417B312C0B9Q24635885-A49A5097-F256-47E3-BB42-08068BE04DA5Q28321001-D73809E5-97CF-471C-909B-86E015B3DE29Q28370102-1C3C07F2-7DB1-4276-9DE7-1E57D48705FBQ28375684-005818AD-501B-4665-BBBB-823ABF1E892AQ28379450-44CEF1D8-05CE-47BE-A320-1D2CD2007CBCQ33430494-22325536-0214-4E6C-AE46-2023849AC0D5Q33765436-2484AA5C-FE78-4CD1-85E6-C35B96387047Q33824537-1DEFA10C-EDCA-49F3-93B0-57E3BA6445D2Q33979979-E9CC7734-E612-4D12-ABA6-24635D5DD671Q34195899-59415229-0D09-4240-BF0F-7A0E4AF257B4Q34761260-9A63380E-4F8B-4FDD-82C7-B8FF14D4D7A2Q35140288-503802BC-D91C-4868-88A9-0A25E0E53213Q35994362-531461AA-44FA-4B79-9B45-8AB5C4890AFEQ36298440-32C159E0-F298-42CF-9571-1A989B097CE2Q36671793-E709E335-942F-48B5-8B08-2C03C5EAAA47Q36734421-B43E8C34-5020-4A0C-B40B-EE9729E8FB63Q36929667-ADD1ECEF-2F78-4289-B676-736A6D935A4EQ36971758-C91BBAD2-6787-466C-BE7C-90611471AD7EQ37334281-B0213CB7-5997-447E-B3DD-F10228D25C96Q37974935-6A9B9F80-6D8F-43C2-ABFA-A3E558D3CD61Q38004603-C522C389-A67C-479B-A56C-63F0F36CC103Q38205012-A65A27F9-FA64-405E-8E10-0B30B4815EF0Q38576391-FF1C7AEC-07B9-4468-8CEC-094A9CDC620CQ40022137-057C1016-EC08-4B74-8489-BB161E12697DQ40616749-0DC68E8A-71A3-45F1-B123-117DA510AECDQ40757488-145BC195-E33E-448C-A154-7FB298ED57DAQ40870134-0BE27DB4-014D-4244-9078-A678984A61A6Q41111818-3794732E-006D-460B-86B1-F53324C88BF8Q41843386-4BDAF393-C8AB-457C-A86D-E15C8F204345Q41877476-C365644A-E372-45B1-BAF3-0918A85AA57EQ41931588-ED6AC3BC-6A30-4E1D-9E42-4401B605B896Q42203665-61406766-457C-464E-B6F8-1AD3095C2A40Q43164316-625EB792-8ABB-40F2-B771-BA3CF7BD3C73Q46430115-20AB4F7A-2E64-4F56-B711-E18B01589C13Q46939633-D5469A36-4E38-49B5-8ADD-FCDEEFEA0560Q46961548-3B44F226-8A99-4DA6-8E23-0B1CE4693FF6Q48231215-868A8C10-A648-4AC1-B176-48311CA45F50Q48317852-BA0D7013-D6EA-4F8D-8CA6-C47EF7A1ECBC
P2860
Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.
description
1970 nî lūn-bûn
@nan
1970年の論文
@ja
1970年学术文章
@wuu
1970年学术文章
@zh
1970年学术文章
@zh-cn
1970年学术文章
@zh-hans
1970年学术文章
@zh-my
1970年学术文章
@zh-sg
1970年學術文章
@yue
1970年學術文章
@zh-hant
name
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@en
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@nl
type
label
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@en
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@nl
prefLabel
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@en
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@nl
P1433
P1476
Biochemical basis for fluorour ...... e inhibition by fluoroacetate.
@en
P2093
P304
P356
10.1001/ARCHNEUR.1970.00480260061008
P577
1970-08-01T00:00:00Z